Advertisement

Assessing Human and Economic Benefits of Cancer Prevention

  • Stephen Joel Coons
  • Benjamin M. Craig

Keywords

Economic Benefit Cancer Prevention Natural Unit Natl Cancer Inst Economic Outcome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aaronson, N.K., S. Ahmedzai, et al. (1993). "The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology." J Natl Cancer Inst 85(5): 365–376.PubMedGoogle Scholar
  2. Bowling, A. (1997). Measuring Health: A Review of Quality of Life Measurement Scales. Philadelphia, Open University Press.Google Scholar
  3. Bowling, A. (2001). Measuring Disease: A Review of Disease-Specific Quality of Life Measurement Scales. Philadelphia, Open University Press.Google Scholar
  4. Brazier, J., J. Roberts, et al. (2002). "The estimation of a preference-based measure of health from the SF-36." J Health Econ 21(2): 271–292.CrossRefPubMedGoogle Scholar
  5. Brown, A.D. and A.M. Garber (1999). "Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing." JAMA 281(4): 347–353.CrossRefPubMedGoogle Scholar
  6. Brown, M. L., J. Lipscomb, et al. (2001). "The burden of illness of cancer: economic cost and quality of life." Annu Rev Public Health 22: 91–113.CrossRefPubMedGoogle Scholar
  7. Bruner, D.W., B. Movsas, et al. (2004). "Outcomes research in cancer clinical trial cooperative groups: the RTOG model." Qual Life Res 13(6): 1025–1041.CrossRefPubMedGoogle Scholar
  8. Cella, D. F., D.S. Tulsky, et al. (1993). "The Functional Assessment of Cancer Therapy scale: development and validation of the general measure." J Clin Oncol 11(3): 570–579.PubMedGoogle Scholar
  9. Cullen, J., M.D. Schwartz, et al. (2004). "Short-term impact of cancer prevention and screening activities on quality of life." J Clin Oncol 22(5): 943–952.CrossRefPubMedGoogle Scholar
  10. Day, R., P.A. Ganz, et al. (1999). "Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study." J Clin Oncol 17(9): 2659–2669.PubMedGoogle Scholar
  11. Donaldson, M.S. (2004). "Taking stock of health-related quality-of-life measurement in oncology practice in the United States." J Natl Cancer Inst Monogr (33): 155–167.CrossRefPubMedGoogle Scholar
  12. Eddy, D.M. (1990). "Screening for cervical cancer." Ann Intern Med 113(3): 214–226.PubMedGoogle Scholar
  13. Esser, M. and H. Brunner (2003). "Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia." Pharmacoeconomics 21(18): 1295–1313.PubMedGoogle Scholar
  14. Fryback, D.G. and B.M. Craig (2004). "Measuring economic outcomes of cancer." J Natl Cancer Inst Monogr (33): 134–141.CrossRefPubMedGoogle Scholar
  15. Gelber, R.D., A. Goldhirsch, et al. (1993). "Evaluation of effectiveness: Q-TWiST The International Breast Cancer Study Group." Cancer Treat Rev 19Suppl A: 73–84.CrossRefPubMedGoogle Scholar
  16. Goldie, S.J., M. Kohli, et al. (2004). "Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine." J Natl Cancer Inst 96(8): 604–615.PubMedGoogle Scholar
  17. Goldie, S.J., M.C. Weinstein, et al. (1999). "The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women." Ann Intern Med 130(2): 97–107.PubMedGoogle Scholar
  18. Guyatt, G.H., D. H. Feeny, et al. (1993). "Measuring health-related quality of life." Ann Intern Med 118(8): 622–629.PubMedGoogle Scholar
  19. Houts, P.S., A. Lipton, et al. (1984). "Nonmedical costs to patients and their families associated with outpatient chemotherapy." Cancer 53(11): 2388–2392.PubMedGoogle Scholar
  20. Johnson, E., F. Dominici, M. Griswold, S. L. Zeger (2003). "Disease cases and their medical costs attributable to smoking: an analysis of the national medical expenditure survey." Journal of Econometrics 112(1): 135–151.CrossRefMathSciNetGoogle Scholar
  21. Karnofsky, D., J. Burchenal (1949). The clinical evaluation of chemotherapeutic agents in cancer. Evaluation of Chemotherapeutic Agents. C. Macleod. New York, Columbia University Press.Google Scholar
  22. Kozma, C.M., C.E. Reeder, et al. (1993). "Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research." Clin Ther 15(6): 1121–1132; discussion 1120.PubMedGoogle Scholar
  23. Kulasingam, S. L. and E. R. Myers (2003). "Potential health and economic impact of adding a human papillomavirus vaccine to screening programs." Jama 290(6): 781–789.CrossRefPubMedGoogle Scholar
  24. Lipscomb, J., M.S. Donaldson, et al. (2004). "Cancer outcomes research and the arenas of application." J Natl Cancer Inst Monogr(33): 1–7.CrossRefPubMedGoogle Scholar
  25. Lipscomb, J. and C.F. Snyder (2002). "The Outcomes of Cancer Outcomes Research: focusing on the National Cancer Institute's quality-of-care initiative." Med Care 40(6 Suppl): III3–10.CrossRefPubMedGoogle Scholar
  26. Litwin, M. S., R.D. Hays, et al. (1998). "The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure." Med Care 36(7): 1002–1012.CrossRefPubMedGoogle Scholar
  27. Loeve, F., M. L. Brown, et al. (2000). "Endoscopic colorectal cancer screening: a cost-saving analysis." J Natl Cancer Inst 92(7): 557–563.CrossRefPubMedGoogle Scholar
  28. Mandelblatt, J.S., W.F. Lawrence, et al. (2002). "Benefits and costs of using HPV testing to screen for cervical cancer." JAMA 287(18): 2372–2381.CrossRefPubMedGoogle Scholar
  29. McDowell, I., C. Newell (1996). Measuring Health: A Guide to Rating Scales and Questionnaires. Philadelphia, Oxford University Press.Google Scholar
  30. NCI (2004). Cancer Progress Report — 2003 Update. Rockville, National Cancer Institute.Google Scholar
  31. O'Brien, B.J., J. Rusthoven, et al. (1993). "Impact of chemotherapy-associated nausea and vomiting on patients' functional status and on costs: survey of five Canadian centres." CMAJ 149(3): 296–302.PubMedGoogle Scholar
  32. Patrick, D.L. and R.A. Deyo (1989). "Generic and disease-specific measures in assessing health status and quality of life." Med Care 27(3 Suppl): S217–232.PubMedGoogle Scholar
  33. Ramsey, S.D., M.T. Mandelson, et al. (2003). "Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer." Gastroenterology 125(6): 1645–1650.CrossRefPubMedGoogle Scholar
  34. Schron, E.B. and S.A. Shumaker (1992). "The integration of health quality of life in clinical research: experiences from cardiovascular clinical trials." Prog Cardiovasc Nurs 7(1): 21–28.Google Scholar
  35. Sculpher, M., M.K. Palmer, et al. (2000). "Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid." Pharmacoeconomics 17(4): 361–370.PubMedGoogle Scholar
  36. Staquet, M., N. Aaronson, et al. (1992). "Health-related quality of life research." Qual Life Res 1:3.CrossRefPubMedGoogle Scholar
  37. Taplin, S.H., W. Barlow, et al. (1995). "Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care." J Natl Cancer Inst 87(6): 417–426.PubMedGoogle Scholar
  38. Tengs, T.O. and A. Wallace (2000). "One thousand health-related quality-of-life estimates." Med Care 38(6): 583–637.CrossRefPubMedGoogle Scholar
  39. Till, J.E., McNeil, B.J., Bush, R.S. (1984). "Measurement of multiple components of quality of life." Cancer Treatment Symposia 1: 177–181.Google Scholar
  40. Tsao, H., G.S. Rogers, et al. (1998). "An estimate of the annual direct cost of treating cutaneous melanoma." J Am Acad Dermatol 38(5 Pt 1): 669–680.PubMedGoogle Scholar
  41. Ubel, P. (2001). Pricing Life: Why it's Time for Health Care Rationing. Cambridge, MIT Press.Google Scholar
  42. Wagner, J.L. (1997). "Cost-effectiveness of screening for common cancers." Cancer Metastasis Rev 16(3–4): 281–294.CrossRefPubMedGoogle Scholar
  43. Ware, J., M. Kosinski, S. Keller (1994). SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, The Health Institute.Google Scholar
  44. Ware, J.E., Jr. and C.D. Sherbourne (1992). "The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection." Med Care 30(6): 473–483.PubMedGoogle Scholar

Copyright information

© Springer Berlin Heidelberg 2005

Authors and Affiliations

  • Stephen Joel Coons
    • 1
  • Benjamin M. Craig
    • 1
  1. 1.College of PharmacyUniversity of ArizonaTucson

Personalised recommendations